Yesterday, on the 9th of October, the NMRC for Hematology hosted a visit from the leadership of the European Hemophilia Consortium (EHC).
International experts visited Moscow as part of the X All-Russian Scientific and Practical Conference on Hemophilia, held with the participation of leading domestic and foreign experts. The conference will be held on the 12th of October 2024.
The delegation included Miguel Farinha, President of the European Hemophilia Consortium, and Olivia Romero, Executive Director of the European Hemophilia Consortium. In addition, Yuri Zhulev, President of the All-Russian Society of Hemophilia, and Daria Camilli, Manager of the European Hemophilia Consortium, visited our Center.
During the visit, the international guests toured the Department of Traumatology and Reconstructive Orthopedics for Patients with Hemophilia. The head of the department - orthopedic traumatologist, hematologist, Professor, Doctor of Medical Sciences, Vladimir Zorenko, showed the foreign experts the infrastructure of the department, including the provision of prosthetic and orthopedic devices for patients, and introduced them to the department staff. He then invited the experts to the ward, where they were able to meet the patients in an informal setting.
“We try not to force the discharge of patients with hemophilia after hip and knee replacements. The average period of rehabilitation and recovery is about three weeks. During this time, patients are under the supervision of doctors and nursing staff. They perform special physical exercises that mimic the natural functions of the limbs. Recovery and rehabilitation are an extremely important part of the treatment process,” Vladimir Y. Zorenko said, answering a question from a foreign representative about the timing of a patient’s recovery after surgery.
Hemophilia is rightfully in the focus of attention of leading hematologists, orthopedists, geneticists, biochemists, sociologists and the international expert community. The success achieved in this field is important for hemophilia and so much more. Developments in this field radically changed modern ideas about the mechanisms of blood clotting and became the foundation of progressive biotechnology of plasma drugs and gene therapy of hereditary abnormalities. Furthermore, these developments have brought patient quality of life closer to normal.
The Russian Federation is on the list of leading countries in providing life-saving drug therapy to patients with hereditary coagulopathies. Every year, hundreds of patients receive surgical and orthopedic treatment as part of the provision of high-tech medical care.
